TME Pharma publishes audited annual report 2022

• Financial visibility extended into December 2023 
   
• Exceptional clinical results generated in brain cancer trial evaluating NOX-A12 in combination with radiotherapy and bevacizumab 
   
• Survival data continue to improve with 83% of patients alive after one year 
   
• 15-month survival data expected in mid-2023

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today its financial results for the fiscal year ending December 31, 2022.

The Annual Report 2022, as approved by the management and supervisory boards on April 20, 2023, is available on TME Pharma’s website (www.tmepharma.com).

"At TME Pharma we are taking on one of the most difficult to treat and underserved cancer indications – the brain cancer called glioblastoma – and 2022 saw us make exceptional clinical progress in our brain cancer program," said Aram Mangasarian, CEO of TME Pharma. "The data generated from the GLORIA study in newly diagnosed glioblastoma patients surpassed our expectations, in particular the interim results in the expansion arm evaluating the triple combination of NOX-A12, radiotherapy and bevacizumab that showed 83% of patients achieved durable partial responses. We recently reported encouraging survival data showing that after 12 months on study (median), 83% of patients were still alive. We are now keenly awaiting more mature survival data in mid-2023, that will allow us to initiate discussions with regulators and design the optimal regulatory path forward for NOX-A12. Our successful new financing transaction extends our cash runway into December 2023 and aligns with our commitment to reduce reliance on convertible debt and our strategy to bring new long-term investors on board and support the company through next clinical results. It will also enable us to maintain our focus on developing novel therapies for cancer patients where there is huge unmet medical need in a significant market that we estimate at $2.5 billion per year." 

About the GLORIA Study

GLORIA (NCT04121455) is TME Pharma’s dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 three additional arms combining NOX-A12 with: A. radiotherapy in patients with complete tumor resection; B. radiotherapy and bevacizumab; and C. radiotherapy and pembrolizumab.  

About the OPTIMUS Study

OPTIMUS (NCT04901741) is TME Pharma’s planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.  

Disclaimer

Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward-looking statements.” Forward-looking statements are based on TME Pharma’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and TME Pharma’s ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made a